CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Visitors trend2W10W9M

4.3000

0.0000

(0.00%)

At close: 04:00PM EDT

4.2900

-0.01

(-0.23%)

After hours:

07:48PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	4.3000
Open	4.2800
Bid	4.2400 x 2200
Ask	4.2500 x 3200
Day's Range	4.2200 - 4.3400
52 Week Range	3.3200 - 7.8000
Volume	1,766,242
Avg. Volume	3,021,618

Market Cap	566.895M
Beta (5Y Monthly)	0.92
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8000
Earnings Date	May 10, 2023 - May 15, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	11.23

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CTI BioPharma Corp.
Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Rating
Fair Value
Economic Moat
14 days agoMorningstar

All

Zacks
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
- Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact'
  Benzinga
- Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker
  Investor's Business Daily
PR Newswire
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive P
Insider Monkey
CTI BioPharma Corp. (NASDAQ:CTIC) Q4 2022 Earnings Call Transcript
CTI BioPharma Corp. (NASDAQ:CTIC) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded. I would now like to introduce your host, Remy Bernarda, CTI Investor Relations. […]